Marc Gillinov

Policy

AtriCure gets FDA nod to try hybrid atrial fibrillation procedure

Updated 8:10 p.m., May 10, 2010. Atricure Inc. (NASDAQ: ATRC), the maker of cardiac surgical ablation systems, has received a conditional nod from the Food and Drug Administration (FDA) to evaluate the safety and efficacy of a hybrid procedure to treat patients with persistent forms of atrial fibrillation. The hybrid procedure “represents a key growth […]

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

News

AtriCure gets European OK for company-critical AtriClip System

AtriCure had tied much of its future success to the AtriClip. Minimally invasive product revenue has fallen at AtriCure in part because of a change in techniques among physicians that's not compatible with some of the company's products. The AtriClip accommodates the "single clamp" approach. Plus, the company thinks this device can also be used for open-heart procedures.